We currently have many active studies and we continually have a number of trials in the developmental stage. The studies range from new ophthalmic devices to treat blepharospasm to retinal gene therapy for inherited genetic disease. At the Oxford Eye Hospital, we are incredibly fortunate to have a number of world class ophthalmologists who devote their time & expertise to clinical trials, across a variety of specialities.
If you are interested in learning more about the studies featured please click on the circle icons below or get in touch via our contact page.
FOCUS: A study to test a new treatment for dry AMD.
Gilead: Efficacy and Safety of Filgotinib in Adults with Active Non-Infectious Uveitis (Humboldt).
Investigation of protein defects in retinal degenerations: This is a five year study assessing patients diagnosed with Retinal Degeneration.
MACTEL: A study to test a The Natural History Observation and Registry Study (NHOR)
MACTEL PHASE 3- NTMT-03: A study to test a new treatment for MACTEL.
MERIT: Macula Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy.
PressOp™ A new spectacle mounted device designed by clinicians to help individuals with Blepharospasm.
Regenerate: A Phase I/II clinical trial of gene therapy for Choroideremia.
SANDMAN: A randomised placebo-controlled trial to assess the effect of melatonin on circadian sleep-wake disturbances in ocular disease.
SCOPE: A natural history study in genetically defined patients with geographic atrophy secondary to age-related macular degeneration.
SeaSTAR: A new treatment for Stargardt disease (STGD).
Somnus: Effects of Ocular Disease on Sleep and Body Clocks.
STAR: The purpose of this study is to find out if vision in patients suffering from choroideremia can be preserved by replacing the defective gene.
UKIRDC: UK Inherited Retinal Disease Consortium.
XIRIUS: A Phase I/II clinical trial of gene therapy for X-linked Retinitis Pigmentosa.